Abstract library

357 results for "KI67 index".
#70 The validity of Ki-67 as a prognostic indicator in patients with appendiceal carcinoid tumor
Introduction: Carcinoid tumors of the appendix are rare and often discovered incidentally through appendectomy. Most are clinically benign but may be associated with metastatic disease. Ki-67, a nuclear protein structurally associated with chromatin, is an excellent marker for measuring cell proliferation and it has been shown to correlate with the outcome in pancreatic and ileocecal carcinoids.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Eric Y Liu
Authors: Liu E, Telem D A, Hwang J, Warner R R P, ...
#1298 Temozolomide-based Second-line Chemotherapy in Patients with Advanced Bronchopulmonary Neuroendocrine Tumours
Introduction: The management of advanced Bronchopulmonary Neuroendocrine Tumours (BP-NET) is not standardized. There are only few clinical studies of Temozolomide (TMZ) as monotherapy or in combination with other agents available for BP-NET.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: PhD Elizaveta Tabaksblat
Authors: Tabaksblat E, Ladekarl M, ...
#1026 Systemic Therapy in Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) and Ki Index 5-10%
Introduction: Phase III trials of sunitinib, everolimus and octreotide lar confirmed that these drugs improved progression-free survival (PFS) in well-differentiated PNET, low/intermediate grade pNET and well-differentiated midgut NETs, respectively. CLARINET is the 1st phase III study that showed PFS benefit of SSA, lanreotide, in both P- and midgut NET and in Ki-67 5-10%.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula J Fonseca
#1567 Pancreatic Neuroendocrine Tumors: Experience from a Single Institute
Introduction: A dedicated multidisciplinary team is necessary in the management of pancreatic neuroendocrine tumor (pNET).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: ...none of the above
Presenting Author: Andrea Caff
Authors: Caff A, Cordio S, Pellegriti G, Russo M, ...
Keywords: pancreatic, Ki-67
#2266 Prognostic Value of the Different Pre-Treatment Biomarkers for Patients with Neuroendocrine Tumors
Introduction: Several inflammatory response materials could be used for prediction of prognosis in cancer patients. The neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), thrombocytosis (the platelets number >400*103/mm3) have been introduced for prognostic scoring system in various cancers.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Biomarkers
Presenting Author: Raluca Roxana Grigorescu
#2269 Can Insulin-Like Growth Factor 1 (IGF-1), IGF-1 Receptor, Connective Tissue Growth Factor and Ki-67 Labelling Index Have a Prognostic Role in Pulmonary Carcinoids?
Introduction: Altered expression of Insulin-like Growth Factor-1 (IGF-1), its receptor (IGF-1R), Connective Tissue Growth Factor (CTGF) and Hypoxia Factor-1 (HIF-1), has been implicated in tumorigenesis. These factors have not been studied systematically in Pulmonary Carcinoids (PCs).
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: M.D, Ph.D. Apostolos Tsolakis
Keywords: IGF-1, IGF-1R, CTGF, HIF-1, Ki-67
#2871 Increase of Ki-67 Index over Time and Influence on All-Cause Mortality in Patients with Neuroendocrine Neoplasms (NEN)
Introduction: Increase of Ki-67 index in NEN over time in relation to progression and a potential influence on prognosis is scarcely studied.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD, PhD Pernille Holmager
#332 Impact of Baseline Ki-67 index and Other Baseline Characteristics on Outcome in a Study of Sunitinib (SU) for the Treatment of Advanced, Progressive Pancreatic Neuroendocrine Tumor (NET)
Introduction: Baseline Ki-67 index and other characteristics may influence outcome in patients (pts) with pancreatic NET; however, the value of Ki-67 and others have not been evaluated prospectively in trials.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Eric Raymond
#352 Predictive factors of tumor control in patients with well differentiated digestive endocrine carcinomas (WDEC) treated with lanreotide
Introduction: The antiproliferative effect of somatostatin analogs was recently demonstrated.
Conference:
Category: Basic
Presenting Author: Dr maxime palazzo
#1781 Clinical Characteristics and Treatment Outcome of Advanced G3 Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)- A Retrospective Analysis
Introduction: Advanced poorly differentiated GEP-NEC are uncommon neoplasms and treated mainly with platinum-based chemotherapy associated with etoposide.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Raluca Roxana Grigorescu